All FDA Antibody Drug Conjugates Heme Malig
Tweetorial
#Goodman_heme

Antibody+Linker+Chemo/toxin
MOA
FDA approvals (trial)
tox (last tweet)

Gemtuzumab ozogamicin
anti-CD33+calicheamicin (DNA breaker)
Frontline AML+7+3 (ALFA,AML15)
Pediatric induction (AAML0531)
RR AML mono-Rx

Brentuximab vedotin
anti-CD30+MMAE (microtubule polym inh)
Frontline HL BV+AVD (ECHELON 1, no OS)
RR HL BV mono-Rx
High risk HL post-ASCT maint (AETHERA,I don't rec)
Frontline CD30+ PTCL BV+CHP (ECHELON2, +OS)
RR systemic anaplastic large cell lymphoma
RR CTCL/cALCL (ALCANZA)

Inotuzumab ozogamicin
anti-CD22+MMAE (+calicheamicin (DNA breaker)
RR B-ALL mono-Rx (INO-VATE, +OS)

Belantamab mafodotin
anti-BCMA+MMAF (microtubule poly inh)
RR multiple myeloma mono-RX (DREAMM-2)

Moxetumomab pasudotox-tdfk
anti-CD22+PE38 (pseudomonas toxin that inhibits EF2)
RR hairy cel leukemia mono-Rx

Polatuzumab vedotin
anti-CD79b+MMAE (microtubule polym inh)
RR DLBC PV+BR (RCT phase II, +OS)

Important Toxicity

Gemtuzumab ozogamicin = VOD
Brentuximab vedotin = Neuropathy
Inotuzumab ozogamicin = VOD
Belantamab mafodotin = Blindness (keratopathy)
Moxetumomab pasudotox-tdfk = HUS+capillary leak
Polatuzumab vedotin = Neuropathy